Zhuhai Kerui Biotechnology: difference between revisions
Diff·revision 20 → 21·09:51, 19 Aug 2025
Difference between revision 20 and revision 21 of Zhuhai Kerui Biotechnology. 15 lines changed; the page grew by 530 bytes.
| Revision 20 — 12:45, 12 Aug 2025 AnaesthesiaAoife (talk) expand §Operations and documentation practice 5,910 bytes +318 | Revision 21 — 09:51, 19 Aug 2025 ProglucagonPia (talk) convert list to prose 6,440 bytes +530 | ||
|---|---|---|---|
| 39 | One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because [[Area percent purity|area percent]] depends on the separation that produced it.{{r|usp1503}} | 39 | One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because [[Area percent purity|area percent]] depends on the separation that produced it.{{r|usp1503}} |
| 40 | 40 | ||
| + | 41 | == Product range == | |
| + | 42 | | Class | Representative listings | Documentation reported | | |
| + | 43 | |---|---|---| | |
| + | 44 | | Incretin analogues | Semaglutide, tirzepatide, retatrutide | Certificate with method, purity, water | | |
| + | 45 | | Research peptides | Repair and secretagogue peptides | Certificate with method | | |
| + | 46 | | SARMs | Bulk | Certificate, purity | | |
| + | 47 | | Raw materials and oils | Bulk | Certificate, limited detail | | |
| + | 48 | ||
| 41 | == References == | 49 | == References == |
| 42 | {{reflist}} | 50 | {{reflist}} |
| ⋮ | ⋮ | ||
| 47 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 55 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| 48 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 56 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 57 | ||
| + | 58 | == See also == | |
| + | 59 | * [[Certificate of analysis]] | |
| + | 60 | * [[Third-party testing]] | |
| + | 61 | * [[Area percent purity]] | |
| + | 62 | * [[Peptide content]] | |
| + | 63 | * [[Research use only]] | |
| 49 | 64 | ||
| 50 | {{DEFAULTSORT:Zhuhai Kerui Biotechnology}} | 65 | {{DEFAULTSORT:Zhuhai Kerui Biotechnology}} |